Executive Summary

  • coIMMUNE® is a clinical stage immuno-oncology company pioneering two novel approaches to engineered cell therapies for the treatment of cancer
  • Advancing a pipeline targeting both hematological and solid tumors based on two proprietary cell therapy technology platforms
    • Allogeneic cytokine-induced killer (CIK) cells based on healthy donor derived PBMCs
    • Autologous RNA-loaded dendritic cells
  • Achieved clinical proof of concept across both of the Company’s two proprietary technology platforms
    • CMN-005 – CARCIK-CD19
      • Completed Phase 1/2a clinical trial, demonstrated significant dose-dependent complete remissions including MRD-negativity with a differentiated safety profile
    • CMN-001 – engineered dendritic cells
      • Ongoing enrollment of Phase 2b trial in treatment naïve renal cell carcinoma
  • FDA/EMEA-compliant GMP manufacturing facility in Durham, North Carolina
  • Strong IP position across both platform technologies
  • Numerous upcoming milestones through 2022